Dr. Lal Path Labs Ltd. has informed the Exchange regarding Allotment of 82750 Shares.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal PathLabs reported FY26 consolidated revenue of ₹27,629 million, up 12.2% from ₹24,614 million in FY25. Profit after tax stood at ₹5,098 million versus ₹4,922 million in FY25, with basic EPS of ₹30.24 (vs ₹29.24 restated). The Board approved a final dividend of ₹4 per share for FY26, taking total dividend for the year to ₹20.5 per share. The company acquired 100% stake in Shahbazkers Diagnostic Centre Private Limited and plans to incorporate a new wholly owned subsidiary in Dubai. Executive Chairman Dr. Arvind Lal and Independent Director Rajit Mehta were reappointed for five-year terms. The auditors issued an unmodified opinion on the financial statements.
Steady financial performance with ~12% revenue growth and maintained profitability margins. Dividend increase signals confidence. Expansion through acquisition and international subsidiary signals growth focus.